Elena Mutti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elena Mutti has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Daniela Veber
15 shared publications- Giuseppe Scalabrino
Città Studi Department, Laboratory of Neuropathology, University of Milan, Milan, Italy
12 shared publications - Ebba Nexo
Aarhus University Hospital
6 shared publications Giovanni Tredici
5 shared publications- Elena Gammella
Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy
3 shared publications Giuseppe Scalabrino
3 shared publications
Latest Publications
- 10 October 2017
- Published by Wiley in ChemBioChem
- Vol. 18 (22) , 2280-2291
Organometallic DNA–B12 Conjugates as Potential Oligonucleotide Vectors: Synthesis and Structural and Binding Studies with Human Cobalamin‐Transport Proteins
The synthesis and structural characterization of Co‐(dN)25‐Cbl (Cbl: cobalamin; dN: deoxynucleotide) and Co‐(dN)39‐Cbl, which are organometallic DNA–B12 conjugates with single DNA strands consisting of 25 and 39 deoxynucleotides, respectively, and binding studies of these two DNA–Cbl conjugates to three homologous human Cbl transporting proteins, transcobalamin (TC), intrinsic factor (IF), and haptocorrin (HC), are reported. This investigation tests the suitability of such DNA–Cbls for the task of eventual in vivo oligonucleotide delivery. The binding of DNA–Cbl to TC, IF, and HC was investigated in competition with either a fluorescent Cbl derivative and Co‐(dN)25‐Cbl, or radiolabeled vitamin B12 (57Co‐CNCbl) and Co‐(dN)25‐Cbl or Co‐(dN)39‐Cbl. Binding of the new DNA–Cbl conjugates was fast and tight with TC, but poorer with HC and IF, which extends a similar original finding with the simpler DNA–Cbl, Co‐(dN)18‐Cbl. The contrasting affinities of TC versus IF and HC for the DNA–Cbl conjugates are rationalized herein by a stepwise mechanism of Cbl binding. Critical contributions to overall affinity result from gradual conformational adaptations of the Cbl‐binding proteins to the DNA–Cbl, which is first bound to the respective β domains. This transition is fast with TC, but slow with IF and HC, with which weaker binding results. The invariably tight interaction of the DNA–Cbl conjugates with TC makes the Cbl moiety a potential natural vector for the specific delivery of oligonucleotide loads from the blood into cells.
- 10 October 2017
- Published by Wiley in ChemBioChem
- Vol. 18 (22) , 2280-2291
Organometallic DNA–B12 Conjugates as Potential Oligonucleotide Vectors: Synthesis and Structural and Binding Studies with Human Cobalamin‐Transport Proteins
The synthesis and structural characterization of Co‐(dN)25‐Cbl (Cbl: cobalamin; dN: deoxynucleotide) and Co‐(dN)39‐Cbl, which are organometallic DNA–B12 conjugates with single DNA strands consisting of 25 and 39 deoxynucleotides, respectively, and binding studies of these two DNA–Cbl conjugates to three homologous human Cbl transporting proteins, transcobalamin (TC), intrinsic factor (IF), and haptocorrin (HC), are reported. This investigation tests the suitability of such DNA–Cbls for the task of eventual in vivo oligonucleotide delivery. The binding of DNA–Cbl to TC, IF, and HC was investigated in competition with either a fluorescent Cbl derivative and Co‐(dN)25‐Cbl, or radiolabeled vitamin B12 (57Co‐CNCbl) and Co‐(dN)25‐Cbl or Co‐(dN)39‐Cbl. Binding of the new DNA–Cbl conjugates was fast and tight with TC, but poorer with HC and IF, which extends a similar original finding with the simpler DNA–Cbl, Co‐(dN)18‐Cbl. The contrasting affinities of TC versus IF and HC for the DNA–Cbl conjugates are rationalized herein by a stepwise mechanism of Cbl binding. Critical contributions to overall affinity result from gradual conformational adaptations of the Cbl‐binding proteins to the DNA–Cbl, which is first bound to the respective β domains. This transition is fast with TC, but slow with IF and HC, with which weaker binding results. The invariably tight interaction of the DNA–Cbl conjugates with TC makes the Cbl moiety a potential natural vector for the specific delivery of oligonucleotide loads from the blood into cells.
- 28 August 2014
- Published by Wiley in Chemistry – A European Journal
- Vol. 20 (41) , 13103-13107
Organometallic B12–DNA Conjugate: Synthesis, Structure Analysis, and Studies of Binding to Human B12‐Transporter Proteins
Design, synthesis, and structural characterization of a B12‐octadecanucleotide are presented herein, a new organometallic B12–DNA conjugate. In such covalent conjugates, the natural B12 moiety may be a versatile vector for controlled in vivo delivery of oligonucleotides to cellular targets in humans and animals, through the endogenous B12 transport systems. Binding of the organometallic B12 octadecanucleotide to the three important human proteins of B12 transport was studied, to examine its structural suitability for the task of eventual in vivo oligonucleotide delivery. Binding was efficient with transcobalamin (TC), but not so efficient with the homologous glycoproteins intrinsic factor and haptocorrin. Binding of the B12 octadecanucleotide to TC suggests the capacity of the B12 moiety to serve as a natural vector for specific transport of single stranded, organometallic oligonucleotide loads from the blood stream into cells.
- 28 August 2014
- Published by Wiley in Chemistry – A European Journal
- Vol. 20 (41) , 13103-13107
Organometallic B12–DNA Conjugate: Synthesis, Structure Analysis, and Studies of Binding to Human B12‐Transporter Proteins
Design, synthesis, and structural characterization of a B12‐octadecanucleotide are presented herein, a new organometallic B12–DNA conjugate. In such covalent conjugates, the natural B12 moiety may be a versatile vector for controlled in vivo delivery of oligonucleotides to cellular targets in humans and animals, through the endogenous B12 transport systems. Binding of the organometallic B12 octadecanucleotide to the three important human proteins of B12 transport was studied, to examine its structural suitability for the task of eventual in vivo oligonucleotide delivery. Binding was efficient with transcobalamin (TC), but not so efficient with the homologous glycoproteins intrinsic factor and haptocorrin. Binding of the B12 octadecanucleotide to TC suggests the capacity of the B12 moiety to serve as a natural vector for specific transport of single stranded, organometallic oligonucleotide loads from the blood stream into cells.
- Open Access
- 20 September 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (9) , e75312
4-Ethylphenyl-Cobalamin Impairs Tissue Uptake of Vitamin B12 and Causes Vitamin B12 Deficiency in Mice
Coβ-4-ethylphenyl-cob(III) alamin (EtPhCbl) is an organometallic analogue of vitamin B12 (CNCbl) which binds to transcobalamin (TC), a plasma protein that facilitates the cellular uptake of cobalamin (Cbl). In vitro assays with key enzymes do not convert EtPhCbl to the active coenzyme forms of Cbl suggesting that administration of EtPhCbl may cause cellular Cbl deficiency. Here, we investigate the in vivo effect of EtPhCbl in mice and its ability, if any, to induce Cbl deficiency. We show that EtPhCbl binds to mouse TC and we examined mice that received 3.5 nmol/24h EtPhCbl (n=6), 3.5 nmol/24h CNCbl (n=7) or NaCl (control group) (n=5) through osmotic mini-pumps for four weeks. We analyzed plasma, urine, liver, spleen, submaxillary glands and spinal cord for Cbl and markers of Cbl deficiency including methylmalonic acid (MMA) and homocysteine (tHcy). Plasma MMA (mean±SEM) was elevated in animals treated with EtPhCbl (1.01±0.12 µmol/L) compared to controls (0.30±0.02 µmol/L) and CNCbl (0.29±0.01 µmol/L) treated animals. The same pattern was observed for tHcy. Plasma total Cbl concentration was higher in animals treated with EtPhCbl (128.82±1.87 nmol/L) than in CNCbl treated animals (87.64±0.93 nmol/L). However, the organ levels of total Cbl were significantly lower in animals treated with EtPhCbl compared to CNCbl treated animals or controls, notably in the liver (157.07±8.56 pmol/g vs. 603.85±20.02 pmol/g, and 443.09±12.32 pmol/g, respectively). Differences between the three groups was analysed using one-way ANOVA and, Bonferroni post-hoc test. EtPhCbl was present in all tissues, except the spinal cord, accounting for 35-90% of total Cbl. In conclusion, treatment with EtPhCbl induces biochemical evidence of Cbl deficiency. This may in part be caused by a compromised tissue accumulation of Cbl.
- 20 September 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (9) , e75312
Open Access4-Ethylphenyl-Cobalamin Impairs Tissue Uptake of Vitamin B12 and Causes Vitamin B12 Deficiency in Mice
Coβ-4-ethylphenyl-cob(III) alamin (EtPhCbl) is an organometallic analogue of vitamin B12 (CNCbl) which binds to transcobalamin (TC), a plasma protein that facilitates the cellular uptake of cobalamin (Cbl). In vitro assays with key enzymes do not convert EtPhCbl to the active coenzyme forms of Cbl suggesting that administration of EtPhCbl may cause cellular Cbl deficiency. Here, we investigate the in vivo effect of EtPhCbl in mice and its ability, if any, to induce Cbl deficiency. We show that EtPhCbl binds to mouse TC and we examined mice that received 3.5 nmol/24h EtPhCbl (n=6), 3.5 nmol/24h CNCbl (n=7) or NaCl (control group) (n=5) through osmotic mini-pumps for four weeks. We analyzed plasma, urine, liver, spleen, submaxillary glands and spinal cord for Cbl and markers of Cbl deficiency including methylmalonic acid (MMA) and homocysteine (tHcy). Plasma MMA (mean±SEM) was elevated in animals treated with EtPhCbl (1.01±0.12 µmol/L) compared to controls (0.30±0.02 µmol/L) and CNCbl (0.29±0.01 µmol/L) treated animals. The same pattern was observed for tHcy. Plasma total Cbl concentration was higher in animals treated with EtPhCbl (128.82±1.87 nmol/L) than in CNCbl treated animals (87.64±0.93 nmol/L). However, the organ levels of total Cbl were significantly lower in animals treated with EtPhCbl compared to CNCbl treated animals or controls, notably in the liver (157.07±8.56 pmol/g vs. 603.85±20.02 pmol/g, and 443.09±12.32 pmol/g, respectively). Differences between the three groups was analysed using one-way ANOVA and, Bonferroni post-hoc test. EtPhCbl was present in all tissues, except the spinal cord, accounting for 35-90% of total Cbl. In conclusion, treatment with EtPhCbl induces biochemical evidence of Cbl deficiency. This may in part be caused by a compromised tissue accumulation of Cbl.
- 1 March 2013
- Published by Elsevier in Brain Research
- Vol. 1503, 1-6
Vitamin B12 dependent changes in mouse spinal cord expression of vitamin B12 related proteins and the epidermal growth factor system
- 1 March 2013
- Published by Elsevier in Brain Research
- Vol. 1503, 1-6
Vitamin B12 dependent changes in mouse spinal cord expression of vitamin B12 related proteins and the epidermal growth factor system
- Open Access
- 1 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e46657
Maximal Load of the Vitamin B12 Transport System: A Study on Mice Treated for Four Weeks with High-Dose Vitamin B12 or Cobinamide
Several studies suggest that the vitamin B12 (B12) transport system can be used for the cellular delivery of B12-conjugated drugs, also in long-term treatment Whether this strategy will affect the endogenous metabolism of B12 is not known. To study the effect of treatment with excess B12 or an inert derivative, we established a mouse model using implanted osmotic minipumps to deliver saline, cobinamide (Cbi) (4.25 nmol/h), or B12 (1.75 nmol/h) for 27 days (n = 7 in each group). B12 content and markers of B12 metabolism were analysed in plasma, urine, kidney, liver, and salivary glands. Both Cbi and B12 treatment saturated the transcobalamin protein in mouse plasma. Cbi decreased the content of B12 in tissues to 33–50% of the level in control animals but did not influence any of the markers examined. B12 treatment increased the tissue B12 level up to 350%. In addition, the transcript levels for methylenetetrahydrofolate reductase in kidneys and for transcobalamin and transcobalamin receptor in the salivary glands were reduced. Our study confirms the feasibility of delivering drugs through the B12 transport system but emphasises that B12 status should be monitored because there is a risk of decreasing the transport of endogenous B12. This risk may lead to B12 deficiency during prolonged treatment.
- 1 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e46657
Open AccessMaximal Load of the Vitamin B12 Transport System: A Study on Mice Treated for Four Weeks with High-Dose Vitamin B12 or Cobinamide
Several studies suggest that the vitamin B12 (B12) transport system can be used for the cellular delivery of B12-conjugated drugs, also in long-term treatment Whether this strategy will affect the endogenous metabolism of B12 is not known. To study the effect of treatment with excess B12 or an inert derivative, we established a mouse model using implanted osmotic minipumps to deliver saline, cobinamide (Cbi) (4.25 nmol/h), or B12 (1.75 nmol/h) for 27 days (n = 7 in each group). B12 content and markers of B12 metabolism were analysed in plasma, urine, kidney, liver, and salivary glands. Both Cbi and B12 treatment saturated the transcobalamin protein in mouse plasma. Cbi decreased the content of B12 in tissues to 33–50% of the level in control animals but did not influence any of the markers examined. B12 treatment increased the tissue B12 level up to 350%. In addition, the transcript levels for methylenetetrahydrofolate reductase in kidneys and for transcobalamin and transcobalamin receptor in the salivary glands were reduced. Our study confirms the feasibility of delivering drugs through the B12 transport system but emphasises that B12 status should be monitored because there is a risk of decreasing the transport of endogenous B12. This risk may lead to B12 deficiency during prolonged treatment.
- 1 January 2012
- Published by Elsevier in Experimental Neurology
- Vol. 233 (1) , 380-390
Cobalamin (vitamin B12) regulation of PrPC, PrPC-mRNA and copper levels in rat central nervous system
- 1 January 2012
- Published by Elsevier in Experimental Neurology
- Vol. 233 (1) , 380-390
Cobalamin (vitamin B12) regulation of PrPC, PrPC-mRNA and copper levels in rat central nervous system
- 18 November 2011
- Published by Wiley in Muscle & Nerve
- Vol. 44 (6) , 957-967
The octapeptide repeat PrPC region and cobalamin-deficient polyneuropathy of the rat
Introduction: Cobalamin (Cbl) deficiency affects the peripheral nervous system (PNS) morphologically and functionally. We investigated whether the octapeptide repeat (OR) region of prion protein (PrPC) (which is claimed to have myelinotrophic properties) is involved in the pathogenesis of rat Cbl‐deficient (Cbl‐D) polyneuropathy. Methods: We intracerebroventricularly administered antibodies (Abs) against the OR region (OR‐Abs) to Cbl‐D rats to prevent myelin damage and maximum nerve conduction velocity (MNCV) abnormalities, and PrPCs to normal rats to reproduce PNS Cbl‐D–like lesions. We measured nerve PrPC levels and MNCV. Results: The OR‐Abs normalized myelin ultrastructure, MNCV values, and tumor necrosis factor (TNF)‐α levels in the sciatic and tibial nerves of Cbl‐D rats. PrPC levels increased in Cbl‐D nerves. The nerves of the PrPC‐treated rats showed typical Cbl‐D lesions, significantly decreased MNCV values, and significantly increased TNF‐α levels. Conclusions: OR‐Abs prevent the myelin damage caused by increased OR regions, and excess TNF‐α is involved in the pathogenesis of Cbl‐D polyneuropathy. Muscle Nerve 2011
- 18 November 2011
- Published by Wiley in Muscle & Nerve
- Vol. 44 (6) , 957-967
The octapeptide repeat PrPC region and cobalamin-deficient polyneuropathy of the rat
Introduction: Cobalamin (Cbl) deficiency affects the peripheral nervous system (PNS) morphologically and functionally. We investigated whether the octapeptide repeat (OR) region of prion protein (PrPC) (which is claimed to have myelinotrophic properties) is involved in the pathogenesis of rat Cbl‐deficient (Cbl‐D) polyneuropathy. Methods: We intracerebroventricularly administered antibodies (Abs) against the OR region (OR‐Abs) to Cbl‐D rats to prevent myelin damage and maximum nerve conduction velocity (MNCV) abnormalities, and PrPCs to normal rats to reproduce PNS Cbl‐D–like lesions. We measured nerve PrPC levels and MNCV. Results: The OR‐Abs normalized myelin ultrastructure, MNCV values, and tumor necrosis factor (TNF)‐α levels in the sciatic and tibial nerves of Cbl‐D rats. PrPC levels increased in Cbl‐D nerves. The nerves of the PrPC‐treated rats showed typical Cbl‐D lesions, significantly decreased MNCV values, and significantly increased TNF‐α levels. Conclusions: OR‐Abs prevent the myelin damage caused by increased OR regions, and excess TNF‐α is involved in the pathogenesis of Cbl‐D polyneuropathy. Muscle Nerve 2011
- 1 February 2011
- Published by Elsevier in Brain Research
- Vol. 1376, 23-30
Cobalamin deficiency-induced changes of epidermal growth factor (EGF)-receptor expression and EGF levels in rat spinal cord
- 1 February 2011
- Published by Elsevier in Brain Research
- Vol. 1376, 23-30
Cobalamin deficiency-induced changes of epidermal growth factor (EGF)-receptor expression and EGF levels in rat spinal cord
- 28 May 2010
- Published by Elsevier in Brain Research
- Vol. 1333, 64-71
Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis
- 28 May 2010
- Published by Elsevier in Brain Research
- Vol. 1333, 64-71
Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis